Asthma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | 90+ Companies are working to improve the Treatment of Space | Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therape

DelveInsight's, "Asthma Pipeline Insight 2023" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Asthma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Asthma NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from Asthma Pipeline Insight Report
• DelveInsight's Asthma Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Asthma.
• The leading Asthma Companies include Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tethererx Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others
• Promising Asthma Pipeline therapies include A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others.
• On June 2023, AstraZeneca announced a study of phase 3 clinical trials for Tezepelumab. A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma.
• On June 2023, Glenmark Pharmaceuticals Ltd India announced a study of phase 2 clinical trials for Revamilast.The primary objective of the study is to evaluate the effect of revamilast on lung function as assessed by Forced Expiratory Volume in one second (FEV1) after the therapy (12 weeks). Secondary objective includes area under curve for FEV1, Change in asthma symptoms, patient / investigator's global assessments and safety. Patients will be followed for safety and efficacy assessment at week 1, 4, 8 12 and 14 after start of therapy.
• On May 2023, GlaxoSmithKline announced a study of phase 3 clinical trials for GSK3511294 (Depemokimab). This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.

To explore more information on the latest breakthroughs in the Asthma Pipeline treatment landscape of the report, click here @ Asthma Pipeline Outlook- https://www.delveinsight.com/report-store/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Asthma Overview
Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen.

For further information, refer to the detailed Asthma Unmet Needs, Asthma Market Drivers, and Asthma Market Barriers, click here for Asthma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Asthma Emerging Drugs Profile
• PT-027: Avillion LLP
• MM09-MG01: Inmunotek S.L.
• FP 025: Foresee Pharmaceuticals
• GB001: Gossamer Bio
• EDP1867: Evelo Biosciences, Inc.
• TQC2731: Chia Tai Tianqing Pharmaceutical Group

Asthma Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Asthma. The companies which have their Asthma drug candidates in the most advanced stage, i.e. phase III include, Avillion LLP.

Request a sample and discover the recent advances in Asthma Ongoing Clinical Trial Analysis and Medications, click here @ Asthma Treatment Landscape- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Asthma Pipeline Report
• Coverage- Global
• Asthma Companies- Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others
• Asthma Pipeline therapies- A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others
• Asthma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Asthma Market Drivers and Asthma Market Barriers, click here @ Asthma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Asthma Executive Summary
3. Asthma: Overview
4. Asthma Pipeline Therapeutics
5. Asthma Pipeline Therapeutic Assessment
6. Asthma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. PT-027: Avillion LLP
9. Mid Stage Products (Phase II/III)
10. PT001: Pearl Therapeutics (AstraZeneca)
11. Mid Stage Products (Phase II)
12. FP 025: Foresee Pharmaceuticals
13. Early Stage Products (Phase I/II)
14. AQ-001S: Aquilon Pharmaceuticals S.A
15. Early Stage Products (Phase I)
16. Itolizumab (EQ001): Equillium
17. Preclinical and Discovery Stage Products
18. KBP7026: KBP Biosciences
19. Inactive Products
20. Asthma Key Companies
21. Asthma Key Products
22. Asthma- Unmet Needs
23. Asthma- Market Drivers and Barriers
24. Asthma- Future Perspectives and Conclusion
25. Asthma Analyst Views
26. Asthma Key Companies
27. Appendix

Got Queries? Find out the related information on Asthma Mergers and acquisitions, Asthma Licensing Activities @ Asthma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.